Polycythemia Vera
146
27
38
74
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
34 trials with published results (23%)
Research Maturity
74 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
8.9%
13 terminated out of 146 trials
85.1%
-1.5% vs benchmark
14%
20 trials in Phase 3/4
46%
34 of 74 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 74 completed trials
Clinical Trials (146)
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: an In-depth Case-control Study
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
A Study of Rusfertide in Adults With Polycythemia Vera in China
CINC424A2X01B Rollover Protocol
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
LOW-PV Continuation
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia